<DOC>
	<DOCNO>NCT00324610</DOCNO>
	<brief_summary>Standard administration capecitabine use 14 day administration . Routine practice several intitution lead use 5 7 day regimen , less toxicity . Purpose : compare pharmacokinetics capecitabine , administer 5 day 7 , compare standard administration ( 14 day 21 ) . The second end point compare toxicity either regimen . Method : Randomized study two group : one standard administration , second 5/7 day regimen</brief_summary>
	<brief_title>Tolerance Pharmacokinetics With Capecitabine 5 Out 7 Days Regimen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically prove breast adenocarcinoma Evaluable measurable metastasis HER2 status 0 1 immnohistochimy negative FISH/CISH Previously treat anthracyclines taxanes Age &gt; = 18 No two previous chemotherapy regimens metastases No nervous central system involvement Hormonal therapy must stop two week enrollment Adequate biologic function Performance status OMS &lt; = 2 Signed inform consent History malignancy , except basocellular cancer , situ cervix carcinoma Gastro intestinal disease might affect absorption capecitabine Cardiac failure angina pectoris uncontrolled Hypersensitivity capecitabine , fluorouracil , one excipient Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Concomitant anticancer therapy ( included hormonotherapy ) Concomitant radiotherapy Treatment sorivudine analog Pregnant breast feeding patient . Contraception method exclude hormonal treatment require . Inclusion experimental protocol within 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>fluoropyrimidines</keyword>
	<keyword>metastasis</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>phase 1-2 study</keyword>
</DOC>